Skip to main content
Top
Published in: Pathology & Oncology Research 2/2009

01-06-2009 | Original Paper

Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

Authors: Sebastian Mannweiler, Peter Amersdorfer, Slave Trajanoski, Jonathan A. Terrett, David King, Gabor Mehes

Published in: Pathology & Oncology Research | Issue 2/2009

Login to get access

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas. As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest. In this study we addressed the cellular distribution and heterogeneity of PSMA expression. Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated. Immunohistochemistry was used to determine the cellular localization, staining intensity and positive cell fraction which were related to tumor type and growth pattern. We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern. A significant number of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the negative range (<10% positive tumor cells). A direct correlation between histological parameters and PSMA expression could not be demonstrated. Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.
Literature
2.
go back to reference Pinto JT, Suffoletto BP, Berzin TM et al (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445–1451PubMed Pinto JT, Suffoletto BP, Berzin TM et al (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445–1451PubMed
3.
go back to reference Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261CrossRefPubMed Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261CrossRefPubMed
4.
go back to reference Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwendt JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701CrossRefPubMed Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwendt JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701CrossRefPubMed
5.
go back to reference Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7:927–936PubMed Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7:927–936PubMed
6.
go back to reference Moreno JG, Croce CM, Fischer R et al (1992) Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 52:6110–6112PubMed Moreno JG, Croce CM, Fischer R et al (1992) Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 52:6110–6112PubMed
7.
go back to reference Silver DA, Pellicer I, Fair WL et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissue. Clin Cancer Res 3:81–85PubMed Silver DA, Pellicer I, Fair WL et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissue. Clin Cancer Res 3:81–85PubMed
8.
go back to reference Chang S, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681PubMed Chang S, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681PubMed
9.
go back to reference Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334CrossRefPubMed Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334CrossRefPubMed
10.
go back to reference Gleason DF (1977) Histologic grading and clinical staging of prostatic carcinoma. In: Tannebaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia, pp 171–197 Gleason DF (1977) Histologic grading and clinical staging of prostatic carcinoma. In: Tannebaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia, pp 171–197
11.
go back to reference Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R (2006) Current practice of Gleason grading of prostate carcinoma. Virchows Arch 448(2):111–118CrossRefPubMed Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R (2006) Current practice of Gleason grading of prostate carcinoma. Virchows Arch 448(2):111–118CrossRefPubMed
12.
go back to reference Douglas G. Altman: Practical Statistics for Medical Research Chapman & Hall/CRC 1 edition (November 22, 1990) Douglas G. Altman: Practical Statistics for Medical Research Chapman & Hall/CRC 1 edition (November 22, 1990)
13.
go back to reference Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3(4):216–225CrossRefPubMed Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3(4):216–225CrossRefPubMed
14.
go back to reference Sodee DB, Sodee AE, Bakale G (2007) Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 37(1):17–28CrossRefPubMed Sodee DB, Sodee AE, Bakale G (2007) Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 37(1):17–28CrossRefPubMed
15.
go back to reference Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66(13):1359–1370CrossRefPubMed Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66(13):1359–1370CrossRefPubMed
16.
go back to reference Ross JS, Sheehan CHE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362PubMed Ross JS, Sheehan CHE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362PubMed
17.
go back to reference Zhigang Z, Wenly S (2004) Prostate stem cell antigen (PSCA) expression in human prostate cancer tissue and its potential role in prostate carcinogenesis and progression of prostate cancer. W J Surg Oncol 2:1–13CrossRef Zhigang Z, Wenly S (2004) Prostate stem cell antigen (PSCA) expression in human prostate cancer tissue and its potential role in prostate carcinogenesis and progression of prostate cancer. W J Surg Oncol 2:1–13CrossRef
18.
go back to reference Bühler P, Wolf P, Gierschner D, Schabel I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U (2008) A bispecific diabody directed against prostate-specific membrane antigen and CD33 induces T-cell mediated lysis of prostate cancer cells. Can Immunol Immunother 57(1):43–52CrossRef Bühler P, Wolf P, Gierschner D, Schabel I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U (2008) A bispecific diabody directed against prostate-specific membrane antigen and CD33 induces T-cell mediated lysis of prostate cancer cells. Can Immunol Immunother 57(1):43–52CrossRef
Metadata
Title
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis
Authors
Sebastian Mannweiler
Peter Amersdorfer
Slave Trajanoski
Jonathan A. Terrett
David King
Gabor Mehes
Publication date
01-06-2009
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2009
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9104-2

Other articles of this Issue 2/2009

Pathology & Oncology Research 2/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine